The ADA and EASD 2019 consensus report recommends SGLT2 inhibitors for the reduction of MACE, CV mortality and hospitalization for HF in patients with diabetes and concomitant HF or CKD [128]. Here, SLC5A2 is linked to chronic kidney disease.